二尖瓣夹子
医学
接收机工作特性
队列
危险分层
弗雷明翰风险评分
临床终点
肌酐
心脏病学
内科学
射血分数
二尖瓣反流
心力衰竭
临床试验
疾病
作者
Elric Zweck,Maximilian Spieker,Patrick Horn,Christos Iliadis,Clemens Metze,Refik Kavsur,Vedat Tiyerili,Georg Nickenig,Stephan Baldus,Malte Kelm,Marc Ulrich Becher,Roman Pfister,Ralf Westenfeld
标识
DOI:10.1016/j.jcin.2021.06.039
摘要
Abstract Objectives The aim of this study was to develop a machine learning (ML)–based risk stratification tool for 1-year mortality in transcatheter mitral valve repair (TMVR) patients incorporating metabolic and hemodynamic parameters. Background The lack of appropriate, well-validated, and specific means to risk-stratify patients with mitral regurgitation complicates the evaluation of prognostic benefits of TMVR in clinical trials and practice. Methods A total of 1,009 TMVR patients from 3 university hospitals within the Heart Failure Network Rhineland were included; 1 hospital (n = 317) served as external validation. The primary endpoint was all-cause 1-year mortality. Model performance was assessed using receiver-operating characteristic curve analysis. In the derivation cohort, different ML algorithms were tested using 5-fold cross-validation. The final model, called MITRALITY (transcatheter mitral valve repair mortality prediction system) was tested in the validation cohort with respect to existing clinical scores. Results Extreme gradient boosting was selected for the MITRALITY score, using only 6 baseline clinical features for prediction (in order of predictive importance): urea, hemoglobin, N-terminal pro–brain natriuretic peptide, mean arterial pressure, body mass index, and creatinine. In the external validation cohort, the MITRALITY score’s area under the curve was 0.783 (95% CI: 0.716-0.849), while existing scores yielded areas under the curve of 0.721 (95% CI: 0.63-0.811) and 0.657 (95% CI: 0.536-0.778) at best. Conclusions The MITRALITY score is a novel, internally and externally validated ML-based tool for risk stratification of patients prior to TMVR, potentially serving future clinical trials and daily clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI